Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069819 | 0.92 | RET (0.35) | CYP2D6CYP3A4HRH3CHRM1KDM5A | |
| SCHEMBL2604735 | 0.85 | CYP3A4 (0.46) | CYP2D6CYP3A4CHRM1WNT1GSK3B | |
| SCHEMBL12733477 | 0.84 | CYP3A4 (0.44) | CYP2D6CYP3A4CHRM1WNT1GSK3B | |
| SCHEMBL20147474 | 0.79 | KDM5A (0.44) | CYP2D6HRH3CHRM1WNT1GSK3B | |
| SCHEMBL21651941 | 0.76 | RET (0.37) | CYP2D6CYP3A4CHRM1KDM5ARET | |
| SCHEMBL20147376 | 0.75 | RET (0.47) | CYP2D6CYP3A4HRH3CHRM1RET | |
| SCHEMBL20158637 | 0.74 | HRH3 (0.35) | CYP2D6HRH3KDM5ARETKCNH2 | |
| SCHEMBL20148011 | 0.72 | RET (0.42) | HRH3RET | |
| SCHEMBL16304087 | 0.72 | DRD2 (0.37) | CYP2D6HRH3KCNH2 | |
| SCHEMBL9911458 | 0.72 | CYP3A4 (0.50) | CYP2D6CYP3A4WNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP2D6 3759/4885CYP3A4 3760/4885HRH3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.